BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17979482)

  • 1. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms.
    Kakar S; Gown AM; Goodman ZD; Ferrell LD
    Arch Pathol Lab Med; 2007 Nov; 131(11):1648-54. PubMed ID: 17979482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hep par-1: a novel immunohistochemical marker for differentiating hepatocellular carcinoma from metastatic carcinoma.
    Hanif R; Mansoor S
    J Coll Physicians Surg Pak; 2014 Mar; 24(3):186-9. PubMed ID: 24613115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma.
    Nguyen T; Phillips D; Jain D; Torbenson M; Wu TT; Yeh MM; Kakar S
    Arch Pathol Lab Med; 2015 Aug; 139(8):1028-34. PubMed ID: 26230595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
    Ibrahim TR; Abdel-Raouf SM
    Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors.
    Amarapurkar AD; Rege JD; Joshi AS; Vaiphei K; Amarapurkar DN
    Indian J Pathol Microbiol; 2006 Jul; 49(3):341-4. PubMed ID: 17001880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-color immunostaining of liver fine needle aspiration biopsies with CD34 and carcinoembryonic antigen. Potential utilization in the diagnosis of primary hepatocellular carcinoma vs. metastatic tumor.
    Yoder M; Zimmerman RL; Bibbo M
    Anal Quant Cytol Histol; 2004 Apr; 26(2):61-4. PubMed ID: 15131892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.
    Shafizadeh N; Ferrell LD; Kakar S
    Mod Pathol; 2008 Aug; 21(8):1011-8. PubMed ID: 18536657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
    Nassar A; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discriminating hepatocellular carcinoma from metastatic carcinoma on fine-needle aspiration biopsy of the liver: the utility of immunocytochemical panel.
    Saleh HA; Aulicino M; Zaidi SY; Khan AZ; Masood S
    Diagn Cytopathol; 2009 Mar; 37(3):184-90. PubMed ID: 19170172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry in the Diagnosis of Hepatocellular Carcinoma.
    Choi WT; Kakar S
    Gastroenterol Clin North Am; 2017 Jun; 46(2):311-325. PubMed ID: 28506367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates.
    Wang L; Vuolo M; Suhrland MJ; Schlesinger K
    Acta Cytol; 2006; 50(3):257-62. PubMed ID: 16780018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunocytochemical localization of polyclonal carcinoembryonic antigen in hepatocellular carcinomas.
    Carrozza MJ; Calafati SA; Edmonds PR
    Acta Cytol; 1991; 35(2):221-4. PubMed ID: 1851357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of glypican-3 in differentiating hepatocellular carcinoma from metastatic liver tumours.
    Majeed S; Mushtaq S; Azam M; Akhtar N; Hussain M; Loya A
    J Pak Med Assoc; 2018 Jul; 68(7):1029-1031. PubMed ID: 30317296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A practical diagnostic approach to hepatic masses.
    Vyas M; Jain D
    Indian J Pathol Microbiol; 2018; 61(1):2-17. PubMed ID: 29567877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral sampling variability in hepatocellular carcinoma: a case report.
    Senes G; Fanni D; Cois A; Uccheddu A; Faa G
    World J Gastroenterol; 2007 Aug; 13(29):4019-21. PubMed ID: 17663522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens.
    Choi WT; Ramachandran R; Kakar S
    Hum Pathol; 2017 May; 63():1-13. PubMed ID: 28087475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver.
    Labib OH; Harb OA; Khalil OH; Baiomy TA; Gertallah LM; Ahmed RZ
    J Gastrointest Cancer; 2020 Mar; 51(1):88-101. PubMed ID: 30784016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic hepatocellular carcinoma presenting as a maxillary sinus mass; a fine needle aspiration cytology diagnosis.
    Gilani SM; Shahab AS; Danforth RD
    Cytopathology; 2013 Dec; 24(6):409-11. PubMed ID: 22765200
    [No Abstract]   [Full Text] [Related]  

  • 19. Differentiation of metastatic follicular thyroid cancer from hepatocellular carcinoma using Hep Par 1.
    Mullin EJ; Metcalfe MS; Maddern GJ
    J Gastroenterol Hepatol; 2007 Nov; 22(11):2047-8. PubMed ID: 17914993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A triple stain of reticulin, glypican-3, and glutamine synthetase: a useful aid in the diagnosis of liver lesions.
    Swanson BJ; Yearsley MM; Marsh W; Frankel WL
    Arch Pathol Lab Med; 2015 Apr; 139(4):537-42. PubMed ID: 25822763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.